P/E ratio for United Therapeutics (UTHR)
P/E ratio as of September 2023 (TTM): 11.9
According to United Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 11.867. At the end of 2021 the company had a P/E ratio of 20.4.
P/E ratio history for United Therapeutics from 2001 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | 20.4 | 56.6% |
| 2020 | 13.0 | -135.8% |
| 2019 | -36.4 | -554.54% |
| 2018 | 8.01 | -48.21% |
| 2017 | 15.5 | 74.61% |
| 2016 | 8.85 | -19.27% |
| 2015 | 11.0 | -40.8% |
| 2014 | 18.5 | -42.83% |
| 2013 | 32.4 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 8.80 | -25.84% | 🇺🇸 USA |
 Eli Lilly LLY | 80.2 | 576.15% | 🇺🇸 USA |
 Baxter BAX | -6.80 | -157.27% | 🇺🇸 USA |
 Gilead Sciences GILD | 17.3 | 45.54% | 🇺🇸 USA |
 Cardinal Health CAH | 88.5 | 645.64% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 4.57 | -61.52% | 🇬🇧 UK |
 Cytokinetics
CYTK | -5.62 | -147.35% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | -5.35 | -145.08% | 🇮🇱 Israel |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.